Strs Ohio bought a new stake in shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 6,100 shares of the biotechnology company’s stock, valued at approximately $119,000.
Other institutional investors have also made changes to their positions in the company. Essex Investment Management Co. LLC bought a new stake in Rocket Pharmaceuticals during the 2nd quarter valued at $306,000. Cobblestone Capital Advisors LLC NY bought a new stake in Rocket Pharmaceuticals during the 2nd quarter valued at $353,000. State of Wisconsin Investment Board bought a new stake in Rocket Pharmaceuticals during the 2nd quarter valued at $391,000. Rhumbline Advisers bought a new stake in Rocket Pharmaceuticals during the 2nd quarter valued at $398,000. Finally, Northern Trust Corp acquired a new position in shares of Rocket Pharmaceuticals during the 1st quarter valued at $620,000. 85.03% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have recently issued reports on the company. LADENBURG THALM/SH SH assumed coverage on Rocket Pharmaceuticals in a research report on Thursday. They set a “buy” rating on the stock. Zacks Investment Research cut Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. William Blair assumed coverage on Rocket Pharmaceuticals in a research report on Wednesday, August 8th. They set a “buy” rating on the stock. Finally, ValuEngine upgraded Rocket Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Rocket Pharmaceuticals has an average rating of “Buy” and a consensus price target of $27.00.
Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.04). equities analysts forecast that Rocket Pharmaceuticals Inc will post -1.9 earnings per share for the current year.
Rocket Pharmaceuticals Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development.
Further Reading: Price to Earnings Ratio (PE) Basics
Want to see what other hedge funds are holding RCKT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rocket Pharmaceuticals Inc (NASDAQ:RCKT).
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.